Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy

Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4+ autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon sustained T cell expression of the co-inhibitory mo...

Full description

Bibliographic Details
Main Authors: Rhoanne C McPherson, Joanne E Konkel, Catriona T Prendergast, John P Thomson, Raffaele Ottaviano, Melanie D Leech, Oliver Kay, Stephanie E J Zandee, Claire H Sweenie, David C Wraith, Richard R Meehan, Amanda J Drake, Stephen M Anderton
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2014-12-01
Series:eLife
Subjects:
immune tolerance
t cell
PD-1
Online Access:https://elifesciences.org/articles/03416

Internet

https://elifesciences.org/articles/03416

Similar Items